Lmy-922

Phase 1

LLuminary Therapeutics

Lmy-922 is one of 22 therapeutic programs targeting Non-Hodgkin Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Non-Hodgkin LymphomaNot yet recruiting

Non-Hodgkin LymphomaPhase 1

Not yet recruiting

Competition

Competitive Landscape

25 competitors in Non-Hodgkin Lymphoma

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 2

3 2

Epkinly

Genmab

Phase 2

2 3

Keytruda

Merck & Co.

Phase 2

1 4

Polivy

Roche

Phase 2

1 5

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

2 6

Cytoxan

BBaxter Healthcare Corporation

Phase 2

1 7

Rayos

RRoxane Laboratories

Phase 2

1 8

Imbruvica

PPharmacyclics LLC.

Phase 2

1 9

Gazyva

Roche

Phase 1

1 10

Actemra

Roche

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 1Not yet recruiting

Non-Hodgkin Lymphoma

NCT07679919

Clinical

Trials by Indication[1]

Non-Hodgkin Lymphoma1 trial

A Phase 1 Study of Allogeneic (γ/δ) BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies

Not yet recruiting·LLuminary Therapeutics·Phase 1·NCT07679919·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lmy-922. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Lmy-922. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Luminary Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: LLuminary Therapeutics

Lmy-922

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Non-Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News